keyword
MENU ▼
Read by QxMD icon Read
search

ASCO

keyword
https://www.readbyqxmd.com/read/29161364/reply-to-re-aligning-the-asco-and-esmo-clinical-benefit-frameworks-or-modern-cancer-therapies
#1
N I Cherny, U Dafni, J Bogaerts, N J Latino, G Pentheroudakis, J-Y Douillard, J Tabernero, C Zielinski, M J Piccart, E G E de Vries
No abstract text is available yet for this article.
November 17, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29147869/hematological-adverse-effects-in-breast-cancer-patients-treated-with-cyclin-dependent-kinase-4-and-6-inhibitors-a-systematic-review-and-meta-analysis
#2
REVIEW
Loay Kassem, Kyrillus S Shohdy, Shaimaa Lasheen, Omar Abdel-Rahman, Thomas Bachelot
BACKGROUND: The introduction of specific cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors significantly improved progression-free survival in hormone receptor-positive metastatic breast cancer. CDK 4/6 inhibitors induce cell cycle arrest via liberating the tumor suppressor retinoblastoma protein from CDK4/6 inhibitory effect. Preliminary studies suggested an increase in the hematological toxicities which might affect the quality of life in such palliative setting. METHODS: We searched PubMed, ASCO, ESMO and San Antonio meeting databases for randomized phase II/III trials in metastatic breast cancer receiving CDK4/6 inhibitors with safety data provided on the incidence of hematological adverse effects...
November 16, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29144866/challenges-in-the-clinical-application-of-the-american-society-of-clinical-oncology-value-framework-a-medicare-cost-benefit-analysis-in-chronic-lymphocytic-leukemia
#3
Erlene K Seymour, Charles A Schiffer, Jonas A de Souza
PURPOSE: The ASCO Value Framework calculates the value of cancer therapies. Given costly novel therapeutics for chronic lymphocytic leukemia, we used the framework to compare net health benefit (NHB) and cost within Medicare of all regimens listed in the National Comprehensive Cancer Network (NCCN) guidelines. METHODS: The current NCCN guidelines for chronic lymphocytic leukemia were reviewed. All referenced studies were screened, and only randomized controlled prospective trials were included...
November 16, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/29140305/probabilistic-prognosis-of-environmental-radioactivity-concentrations-due-to-radioisotopes-discharged-to-water-bodies-from-nuclear-power-plants
#4
Juan Tomás Zerquera, Juan C Mora, Beatriz Robles
Due to their very low values, the complexity of comparing the contribution of nuclear power plants (NPPs) to environmental radioactivity with modeled values is recognized. In order to compare probabilistic prognosis of radioactivity concentrations with environmental measurement values, an exercise was performed using public data of radioactive routine discharges from three representative Spanish nuclear power plants. Specifically, data on liquid discharges from three Spanish NPPs: Almaraz, Vandellós II, and Ascó to three different aquatic bodies (river, lake, and coast) were used...
November 15, 2017: Toxics
https://www.readbyqxmd.com/read/29138191/evaluation-of-guidelines-regarding-surgical-treatment-of-breast-cancer-using-the-agree-instrument-a-systematic-review
#5
Xin Lei, Fengtao Liu, Shuying Luo, Ya Sun, Liling Zhu, Fengxi Su, Kai Chen, Shunrong Li
OBJECTIVES: Many clinical practice guidelines and consensus statements (CPGs/consensus statements) have been developed for the surgical treatments for breast cancer. This study aims to evaluate the quality of these CPGs/consensus statements. METHODS: We systematically searched the PubMed and EMBASE databases, as well as four guideline repositories, to identify CPGs and consensus statements regarding surgical treatments for breast cancer between January 2009 and December 2016...
November 14, 2017: BMJ Open
https://www.readbyqxmd.com/read/29137449/differential-side-effects-profile-in-patients-with-mcrpc-treated-with-abiraterone-or-enzalutamide-a-meta-analysis-of-randomized-controlled-trials
#6
REVIEW
Raphael B Moreira, Marcio Debiasi, Edoardo Francini, Pier V Nuzzo, Guillermo De Velasco, Fernando C Maluf, Andre P Fay, Joaquim Bellmunt, Toni K Choueiri, Fabio A Schutz
Background: Abiraterone and enzalutamide are currently approved for mCRPC patients. Both drugs have distinct mechanisms of action and may have different toxicity profile. There are limited data comparing the side effects of abiraterone and enzalutamide. We performed a meta-analysis of randomized controlled trials (RCT) to better characterize the risk of adverse events associated with both drugs. Methods: We performed a literature search on MEDLINE for studies reporting abiraterone and enzalutamide side effects from January 1966 to July 31, 2015...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29137342/incidence-and-relative-risk-of-cutaneous-squamous-cell-carcinoma-with-single-agent-braf-inhibitor-and-dual-braf-mek-inhibitors-in-cancer-patients-a-meta-analysis
#7
Ling Peng, Yina Wang, Yun Hong, Xianghua Ye, Peng Shi, Junyan Zhang, Qiong Zhao
Background: BRAF inhibitor and dual BRAF/MEK inhibitors have been approved for the treatment of BRAF-mutated melanoma. Cutaneous squamous cell carcinoma (cuSCC) is an adverse event associated with these drugs. The contribution of BRAF inhibitor and dual BRAF/MEK inhibitors to cuSCC are still unknown. We performed this meta-analysis to determine the overall incidence and relative risk of cuSCC in cancer patients treated with these drugs. Results: A total of 7,442 patients from 24 primary studies were included...
October 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29127786/development-and-initial-testing-of-the-brief-adolescent-smoking-curiosity-scale-ascos
#8
Georges E Khalil, Karen S Calabro, Alexander V Prokhorov
BACKGROUND: Although the reasons behind tobacco smoking at young age are complex, research has identified curiosity as a potent driver of smoking among adolescents. OBJECTIVE: The objective of the current study is to develop and provide initial evidence of reliability and validity of a short scale assessing smoking curiosity among adolescents (first measure of its kind). In particular, we developed and tested the adolescent smoking curiosity scale (ASCOS). METHODS: After scale development, 101 adolescents completed a survey on smoking-related measures, including ASCOS (June to August 2014)...
November 7, 2017: Addictive Behaviors
https://www.readbyqxmd.com/read/29114591/tweet-for-the-cure-a-snapshot-of-twitter-usage-by-3%C3%A2-u-s-oncologic-professional-societies
#9
Sachin R Jhawar, Vinay Prabhu, Matthew S Katz, Sabin B Motwani
Purpose: Medical societies are incorporating Twitter to communicate with their members and connect with patients. This study compares the online presence of 3 major oncologic societies. Methods and materials: All available tweets in 2014 by the American Society for Radiation Oncology (ASTRO), American Society of Clinical Oncology (ASCO), and Society of Surgical Oncology (SSO) were collected. We analyzed whether posts were original content or retweets. The monthly tweet rate was followed to assess trends...
July 2017: Advances in Radiation Oncology
https://www.readbyqxmd.com/read/29113162/retrospective-analysis-of-the-association-between-human-epidermal-growth-factor-receptor-2-amplification-and-chromosome-enumeration-probe-17-status-in-patients-with-breast-cancer
#10
Xiaoyu Hu, Yanan Li, Dong Yuan, Ruohan Li, Lingquan Kong, Hongyuan Li, Zhu Yang, Qiubo Yu
The aim of the present study was to identify potential human epidermal growth factor receptor 2 (HER2) amplification, according to American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP) 2013 HER2 testing guidelines, in patients previously determined not to possess HER2 amplification, in accordance with previous 2007 guidelines. Potential discrepancies may arise from chromosome enumeration probe 17 (CEP17) amplification, deletion, polysomyor monosomy. HER2, CEP17, tumor protein p53 (TP53) and retinoic acid receptor α (RARA) genes from 67 patient specimens with suspected amplification, polysomy or monosomy of CEP17 were analyzed using fluorescence in situ hybridization...
November 2017: Oncology Letters
https://www.readbyqxmd.com/read/29112709/re-aligning-the-asco-and-esmo-clinical-benefit-frameworks-for-modern-cancer-therapies
#11
J C Del Paggio, R Sullivan, W M Hopman, C M Booth
No abstract text is available yet for this article.
November 3, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29112463/alcohol-and-cancer-a-statement-of-the-american-society-of-clinical-oncology
#12
Noelle K LoConte, Abenaa M Brewster, Judith S Kaur, Janette K Merrill, Anthony J Alberg
Alcohol drinking is an established risk factor for several malignancies, and it is a potentially modifiable risk factor for cancer. The Cancer Prevention Committee of the American Society of Clinical Oncology (ASCO) believes that a proactive stance by the Society to minimize excessive exposure to alcohol has important implications for cancer prevention. In addition, the role of alcohol drinking on outcomes in patients with cancer is in its formative stages, and ASCO can play a key role by generating a research agenda...
November 7, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29106810/stereotactic-body-radiotherapy-for-early-stage-non-small-cell-lung-cancer-american-society-of-clinical-oncology-endorsement-of-the-american-society-for-radiation-oncology-evidence-based-guideline
#13
Bryan J Schneider, Megan E Daly, Erin B Kennedy, Mara B Antonoff, Stephen Broderick, Jill Feldman, Shruti Jolly, Bryan Meyers, Gaetano Rocco, Chad Rusthoven, Ben J Slotman, Daniel H Sterman, Brendon M Stiles
Purpose The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on treatment with stereotactic body radiotherapy (SBRT) for patients with early-stage non-small-cell lung cancer. ASCO has a policy and set of procedures for endorsing and/or adapting clinical practice guidelines that have been developed by other professional organizations. Methods The ASTRO Evidence-Based Guideline for Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer was reviewed for developmental rigor by methodologists...
November 6, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29094172/essential-role-of-radiation-therapy-for-the-treatment-of-pancreatic-cancer-novel-study-concepts-and-established-treatment-recommendations
#14
REVIEW
Sophie Dobiasch, Nicole L Goerig, Rainer Fietkau, Stephanie E Combs
BACKGROUND: Pancreatic cancer is one of the most aggressive human tumors and the incidence has increased over the last 6 years. In the majority of cases the disease is already in an advanced stage at the time of diagnosis where surgery, the only curative treatment, is no longer an option and explains the still abysmal overall survival. The role of radiation therapy as treatment option for patients with pancreatic cancer is controversially discussed although radiation oncology has emerged as a central pillar in the combined oncological treatment...
November 1, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29094101/secondary-prevention-of-cervical-cancer-asco-resource-stratified-clinical-practice-guideline
#15
Jose Jeronimo, Philip E Castle, Sarah Temin, Lynette Denny, Vandana Gupta, Jane J Kim, Silvana Luciani, Daniel Murokora, Twalib Ngoma, Youlin Qiao, Michael Quinn, Rengaswamy Sankaranarayanan, Peter Sasieni, Kathleen M Schmeler, Surendra S Shastri
Purpose: To provide resource-stratified, evidence-based recommendations on the secondary prevention of cervical cancer globally. Methods: ASCO convened a multidisciplinary, multinational panel of oncology, primary care, epidemiology, health economic, cancer control, public health, and patient advocacy experts to produce recommendations reflecting four resource-tiered settings. A review of existing guidelines, a formal consensus-based process, and a modified ADAPTE process to adapt existing guidelines were conducted...
October 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/29090083/gastrointestinal-adverse-effects-of-cyclin-dependent-kinase-4-and-6-inhibitors-in-breast-cancer-patients-a-systematic-review-and-meta-analysis
#16
REVIEW
Kyrillus S Shohdy, Shaimaa Lasheen, Loay Kassem, Omar Abdel-Rahman
BACKGROUND: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors show promising results in metastatic breast cancer. However, an increased incidence of adverse events is remarkable. Among others, gastrointestinal (GI) involvement is of momentous impact on patients and their quality of life. METHODS: Our search included PubMed, ASCO, ESMO and SABCS databases. Randomized phase II/III trials in metastatic breast cancer receiving CDK4/6 inhibitors were identified and considered relevant based on providing a sufficient safety profile on the incidence of adverse GI effects...
November 2017: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29083976/letter-corrected-net-health-benefit-calculations-for-enzalutamide-using-asco-value-framework-guidelines-and-nccn-evidence-blocks
#17
Scott Flanders, Bruce Brown, Marjan Massoudi, Neil Schultz, Krishnan Ramaswamy
This research was funded by Astellas Pharma and Medivation, which was acquired by Pfizer in 2016. Astellas Pharma and Medivation are the co-developers of enzalutamide. Flanders, Brown, Massoudi, and Schultz are employees of Astellas Pharma. Ramaswamy is an employee of Pfizer and holds stock in Johnson & Johnson. Flanders holds stock in Johnson & Johnson, AbbVie, and Abbott Labs.
November 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29071398/-metastatic-castration-resistant-prostate-cancer-use-of-cabazitaxel-taking-into-consideration-current-data
#18
J E Gschwend, P Albers, M Bögemann, P Goebell, A Heidenreich, J Klier, F König, S Machtens, K Pantel, C Thomas
BACKGROUND: At the 2016 ASCO annual meeting, new data from two randomized phase III studies concerning taxane-based chemotherapy as a treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) were presented. OBJECTIVES: The focus is on the clinical impact of these data. MATERIALS AND METHODS: A group of German experts in the field of urogenital-oncologic expertise discussed the clinical impact with respect to the current data...
October 25, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/29070992/news-from-asco-2017
#19
Marcus Schmidt, Tanja Fehm, Cornelia Liedtke, Volkmar Müller
No abstract text is available yet for this article.
September 2017: Breast Care
https://www.readbyqxmd.com/read/29064744/radiation-therapy-for-oropharyngeal-squamous-cell-carcinoma-american-society-of-clinical-oncology-endorsement-of-the-american-society-for-radiation-oncology-evidence-based-clinical-practice-guideline
#20
Harry Quon, Neha Vapiwala, Arlene Forastiere, Erin B Kennedy, David J Adelstein, Holly Boykin, Joseph A Califano, F Chris Holsinger, Brian Nussenbaum, David I Rosenthal, Lillian L Siu, John N Waldron
Purpose The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on radiation therapy in oropharyngeal squamous cell carcinoma (OPSCC) that was determined to be relevant to the American Society of Clinical Oncology (ASCO) membership. After applying standard critical appraisal policy and endorsement procedures, ASCO chose to endorse the ASTRO guideline. Methods The ASTRO guideline was reviewed by ASCO content experts for clinical accuracy and by ASCO methodologists for developmental rigor...
October 24, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
33466
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"